SCHEMBL2863066

SCHEMBL2863066

COC(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.44
HIF1A Q16665 3/20 0.41
DGAT1 O75907 1/20 0.40
CHEK1 O14757 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.39
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA9 Q16790 4/20 0.38
CA12 O43570 2/20 0.38
CA7 P43166 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
LIPG Q9Y5X9 3/20 0.37
LPL P06858 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31061615 1.00 CSF1R (0.44) CSF1RHIF1ADGAT1CHEK1KDM4E
SCHEMBL389893 0.89 CSF1R (0.44) CSF1RHIF1ADGAT1KDM4EGAA
SCHEMBL4831364 0.87 CSF1R (0.44) CSF1RHIF1ADGAT1CHEK1KDM4E
SCHEMBL1723521 0.87 ALDH1A1 (0.50) CSF1RHIF1ADGAT1CHEK1KDM4E
SCHEMBL25035049 0.87 HIF1A (0.43) CSF1RHIF1ADGAT1KDM4EGAA
SCHEMBL5064664 0.87 UCHL1 (0.43) CSF1RHIF1AKDM4EGAACA1
SCHEMBL28483767 0.87 AAK1 (0.44) CSF1RHIF1ADGAT1CA1CA2
SCHEMBL28913511 0.87 AAK1 (0.39) CSF1RHIF1ADGAT1KDM4ECA1
SCHEMBL424243 0.87 TDP1 (0.52) HIF1ADGAT1KDM4ECA1CA2
SCHEMBL425734 0.86 MKNK1 (0.45) CSF1RHIF1ADGAT1CHEK1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2026-05-07 US disclosed
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof GLAXOSMITH KLINE LLC (US) 2026-03-10 US disclosed
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 US disclosed
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 US disclosed
US-12522587-B2 Cancer treatments targeting cancer stem cells REMEDY PLAN, INC. (US) 2026-01-13 US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 US disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 EP disclosed
US-20240368132-A1 ROCK2 INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-11-07 US disclosed
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-07-25 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
WO-2008109943-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF CYTOPIA RESEARCH PTY LTD (AU) 2008-09-18 WO disclosed
US-7417169-B2 Amino alcohol derivatives, medicinal composition containing the same, and use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-08-26 US disclosed
US-20070078184-A1 Amino alcohol derivatives, medicinal composition containing the same, and use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-04-05 US disclosed
EP-1679304-A1 AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE Kissei Pharmaceutical Co., Ltd. (JP) 2006-07-12 EP disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
EP-1546086-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ASTELLAS PHARMA INC. (JP) 2005-04-28 US disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed
WO-2004002939-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368132-A1 ROCK2 INHIBITORS AND USES THEREOF ROCK2, ROCK1, RHOA CSF1R 1883/4885HIF1A 2606/4885DGAT1 2416/4885
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA CSF1R 1445/4885HIF1A 4316/4885DGAT1 3596/4885
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS CAMKK2, CAMKK1, CAMK1 CSF1R 3739/4885HIF1A 1068/4885DGAT1 3886/4885
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 CSF1R 4215/4885HIF1A 1566/4885DGAT1 1326/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA CSF1R 2208/4885HIF1A 3233/4885DGAT1 1628/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA CSF1R 2208/4885HIF1A 3233/4885DGAT1 1628/4885
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof JAK1, JAK2, JAK3 CSF1R 374/4885HIF1A 808/4885DGAT1 4584/4885
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 CSF1R 4341/4885HIF1A 4059/4885DGAT1 1563/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 CSF1R 4423/4885HIF1A 1414/4885DGAT1 2011/4885
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, MALT1, BCL6 CSF1R 845/4885HIF1A 109/4885DGAT1 1215/4885
US-20070078184-A1 Amino alcohol derivatives, medicinal composition containing the same, and use of these ADRB2, ADRA2A, ADRA1A CSF1R 2967/4885HIF1A 2362/4885DGAT1 2352/4885
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 CSF1R 2375/4885HIF1A 2624/4885DGAT1 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.